News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

pSivida Corp (PSDV) Presents Preclinical Data Demonstrating Sustained Release Of Avastin Using Tethadur At Association for Research in Vision & Ophthalmology Annual Meeting


5/6/2014 7:06:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida’s Tethadur™ technology to provide sustained release of Avastin at the 14th Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES